Additional Information
Book Details
Abstract
Now fully revised and updated, Dr. Barbara Gladson's Pharmacology for Rehabilitation Professionals, 2nd Edition, remains your best resource for understanding how various drugs affect patients during therapeutic exercise and rehabilitation. Using case studies and engaging activities, it helps you apply essential pharmacology information directly to rehabilitation practice. New chapters, a new reader-friendly design, new artwork, and more enhance the text and bring you up to date with both basic pharmacologic principles as well as the mechanism of action and side effects of drugs commonly seen in rehabilitation practice.
- Helps you develop effective exercise programs by providing drug/exercise interactions from a pharmacokinetics perspective. You willl clearly see the implications for exercise for each specific condition and medication.
- Presents case studies in every chapter that demonstrate the effects of various drugs on the diagnosis, prognosis, and interventions in physical therapy, so you can more easily monitor patients for adverse drug effects.
- Features engaging activities in every chapter, ranging from patient interviews to challenging, real-life questions, helping you retain and apply what you've learned.
- Encourages you to use the latest research in your clinical decision making with evidence-based content incorporated throughout.
- Simplifies the complex topic of pharmacokinetics so that you will fully understand how it affects your individual patients and your care plans.
- Guides you in using the Internet for online drug information with references to specific sites, and when and how to use them to their fullest potential.
- Discusses lifespan considerations such as age, physical differences, and obesity, as well as the latest information on diabetes and glucose testing.
- A new chapter on Complementary and Alternative Medicine in Pharmacology covers popular herbal and alternative products used to promote health, as well as herbal remedies used during menopause and in the treatment of cancer, helping you recognize the impact of herbals on your patients' symptoms and response to therapy.
- A new chapter on Drugs Affecting the Integumentary System discusses skin disorders and their pharmacological treatment, prophylactic and debriding agents, antiseptics, and more.
- A new chapter on Nutrition and Pharmacology provides current information on vitamins and minerals, enteral and parenteral nutrition, and food and drug interactions -- important topics that affect rehabilitation outcomes.
- Updated drug information and new drugs are added throughout the text, keeping you up to date with current pharmacological information as it pertains to rehabilitation.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front cover | Cover | ||
| Pharmacology for Rehabilitation Professionals Second Edition | iii | ||
| Copyright page | iv | ||
| CONTRIBUTORS | vi | ||
| PREFACE | vii | ||
| ACKNOWLEDGMENTS | viii | ||
| TABLE OF CONTENTS | ix | ||
| SECTION ONE Principles of Pharmacology | 1 | ||
| CHAPTER 1. Introduction | 2 | ||
| WHAT IS PHARMACOLOGY? | 2 | ||
| WHY SHOULD PHYSICAL THERAPISTS STUDY PHARMACOLOGY? | 3 | ||
| DRUG DEVELOPMENT AND REGULATION PROCESS | 3 | ||
| ELEMENTS OF A PRESCRIPTION | 7 | ||
| CONTROLLED SUBSTANCES | 7 | ||
| DRUG NAMING AND CLASSIFICATION SYSTEMS | 8 | ||
| REFERENCES | 9 | ||
| CHAPTER 2. Pharmacodynamics: Mechanism of Action | 12 | ||
| TARGETS FOR DRUG ACTION | 12 | ||
| DRUG–RECEPTOR INTERACTIONS | 14 | ||
| DRUG SAFETY | 17 | ||
| REFERENCES | 19 | ||
| CHAPTER 3. Pharmacokinetics and Drug Dosing | 21 | ||
| WHAT IS PHARMACOKINETICS? | 21 | ||
| MOVEMENT OF DRUGS ACROSS CELL MEMBRANES | 21 | ||
| DRUG ABSORPTION AND ROUTES OF ADMINISTRATION | 23 | ||
| DISTRIBUTION OF DRUGS | 27 | ||
| METABOLISM | 28 | ||
| DRUG ELIMINATION | 30 | ||
| MATHEMATIC BASIS OF PHARMACOKINETICS | 30 | ||
| FIRST-ORDER ELIMINATION AND DOSING | 31 | ||
| FACTORS AFFECTING PHARMACOKINETICS | 32 | ||
| REFERENCES | 34 | ||
| CHAPTER 4. Adverse Drug Reactions | 37 | ||
| RISK/BENEFIT RATIO | 37 | ||
| CLASSIFICATION OF ADVERSE DRUG REACTIONS | 37 | ||
| DRUG–DRUG INTERACTIONS | 41 | ||
| FOOD–DRUG INTERACTIONS | 42 | ||
| DRUG ALLERGY AND DRUG-INDUCED ILLNESSES | 43 | ||
| REFERENCES | 45 | ||
| SECTION TWO Autonomic and Cardiovascular Pharmacology | 47 | ||
| CHAPTER 5. Drugs Acting on the Autonomic Nervous System | 48 | ||
| AUTONOMIC NERVOUS SYSTEM | 48 | ||
| DRUGS THAT MIMIC THE PARASYMPATHETIC NERVOUS SYSTEM | 54 | ||
| MUSCARINIC ANTAGONISTS | 55 | ||
| DRUGS AFFECTING THE SYMPATHETIC (ADRENERGIC) NERVOUS SYSTEM | 59 | ||
| PHYSIOLOGY AND FUNCTION OF THE BLADDER | 62 | ||
| REFERENCES | 64 | ||
| CHAPTER 6. Antihypertensive Agents | 66 | ||
| HYPERTENSION | 66 | ||
| PHYSIOLOGY AND PATHOPHYSIOLOGY OF BLOOD PRESSURE | 66 | ||
| DIURETICS | 70 | ||
| β-ADRENOCEPTOR BLOCKERS | 73 | ||
| α-ADRENOCEPTOR BLOCKERS | 74 | ||
| DUAL α- AND β-BLOCKERS | 75 | ||
| CENTRAL ACTING α₂-AGONISTS | 75 | ||
| VASODILATORS | 75 | ||
| ACE INHIBITORS AND ACE RECEPTOR BLOCKERS (ACE RECEPTOR ANTAGONISTS) | 76 | ||
| PLASMA RENIN INHIBITORS | 77 | ||
| MANAGEMENT OF HYPERTENSIVE EMERGENCIES | 77 | ||
| GUIDELINES FOR THE TREATMENT OF HYPERTENSION | 77 | ||
| THERAPEUTIC CONCERNS ABOUT ANTIHYPERTENSIVE AGENTS | 78 | ||
| REFERENCES | 83 | ||
| CHAPTER 7. Drug Therapy for Coronary Atherosclerosis and Its Repercussions | 86 | ||
| ISCHEMIC HEART DISEASE | 86 | ||
| PATHOPHYSIOLOGY AND TREATMENT OF ISCHEMIC HEART DISEASE AND ANGINA | 86 | ||
| THROMBOSIS AND ANTITHROMBOTIC THERAPY | 91 | ||
| PHARMACOLOGIC PREVENTION AND MANAGEMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM | 97 | ||
| PHARMACOLOGIC MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE | 98 | ||
| PHARMACOLOGIC MANAGEMENT OF UNSTABLE ANGINA AND MYOCARDIAL INFARCTION | 99 | ||
| ATHEROSCLEROSIS AND LIPID-LOWERING DRUGS | 99 | ||
| REFERENCES | 105 | ||
| CHAPTER 8. Drug Therapy for Congestive Heart Failure and Cardiac Arrhythmias | 109 | ||
| DRUG TREATMENT FOR CONGESTIVE HEART DISEASE | 109 | ||
| DRUG TREATMENT FOR CARDIAC ARRHYTHMIA | 114 | ||
| REFERENCES | 122 | ||
| CHAPTER 9. Drug Therapy for Pulmonary Disorders | 125 | ||
| REGULATION OF RESPIRATION AND AIRWAY SMOOTH MUSCLE TONE | 125 | ||
| BRONCHIAL ASTHMA | 125 | ||
| OTHER DRUGS USEFUL IN RESPIRATORY DISORDERS | 133 | ||
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 134 | ||
| CYSTIC FIBROSIS | 136 | ||
| THERAPEUTIC CONCERNS WITH DRUGS FOR RESPIRATORY DISORDERS | 137 | ||
| REFERENCES | 138 | ||
| SECTION THREE Pain Control | 141 | ||
| CHAPTER 10. Anesthetic Agents | 142 | ||
| TYPES OF ANESTHESIA | 142 | ||
| GENERAL ANESTHESIA | 142 | ||
| REGIONAL AND LOCAL ANESTHESIA | 147 | ||
| REFERENCES | 150 | ||
| CHAPTER 11. Drugs for the Treatment of Pain and Inflammation | 152 | ||
| PHYSIOLOGY OF PAIN | 152 | ||
| MORPHINE AND SIMILAR OPIOID ANALGESICS | 155 | ||
| ANTI-INFLAMMATORY AGENTS | 161 | ||
| NEUROPATHIC PAIN | 168 | ||
| PAIN RELATED TO CANCER | 168 | ||
| REFERENCES | 170 | ||
| CHAPTER 12. Drug Treatment for Arthritis-Related Conditions | 174 | ||
| DRUG TREATMENT OF RHEUMATOID ARTHRITIS | 174 | ||
| DRUG TREATMENT OF GOUT | 179 | ||
| DRUG TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | 181 | ||
| DRUG TREATMENT OF OSTEOARTHRITIS | 184 | ||
| REFERENCES | 187 | ||
| SECTION FOUR Endocrine Pharmacology | 190 | ||
| CHAPTER 13. Selective Topics in Endocrine Pharmacology | 191 | ||
| OVERVIEW OF THE ENDOCRINE SYSTEM | 191 | ||
| PATHOPHYSIOLOGY AND PHARMACOLOGY RELATED TO THE PITUITARY GLAND | 191 | ||
| THYROID DISEASES | 197 | ||
| DRUG THERAPY FOR ADRENAL DYSFUNCTION | 200 | ||
| DRUG TREATMENT FOR THE REPRODUCTIVE SYSTEM | 202 | ||
| REFERENCES | 213 | ||
| CHAPTER 14. Drug Treatment for Osteoporosis and Diabetes | 216 | ||
| DRUG TREATMENT FOR OSTEOPOROSIS | 216 | ||
| DRUG TREATMENT FOR DIABETES | 222 | ||
| EXERCISE AND DIABETES TREATMENT: THERAPEUTIC CONCERNS | 240 | ||
| REFERENCES | 243 | ||
| SECTION FIVE Neurologic Pharmacology | 248 | ||
| CHAPTER 15. Drugs for Epilepsy and Attention-Deficit/Hyperactivity Disorder | 249 | ||
| OVERVIEW OF EPILEPSY | 249 | ||
| ANTIEPILEPTIC DRUGS | 251 | ||
| GENERAL APPROACH TO THE MANAGEMENT OF EPILEPSY | 254 | ||
| ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | 257 | ||
| REFERENCES | 260 | ||
| CHAPTER 16. Antispasticity Medications and Skeletal Muscle Relaxants | 262 | ||
| PHYSIOLOGY OF SPASTICITY AND MUSCLE SPASMS | 262 | ||
| FACTORS IN DETERMINING TREATMENTS OF SPASTICITY | 262 | ||
| SPASTICITY | 262 | ||
| MUSCLE RELAXANTS | 275 | ||
| REFERENCES | 277 | ||
| CHAPTER 17. Pharmacologic Management of Degenerative Neurologic Disorders | 279 | ||
| INTRODUCTION | 279 | ||
| PARKINSON’S DISEASE: EPIDEMIOLOGY AND PATHOLOGY | 279 | ||
| MULTIPLE SCLEROSIS: PATHOLOGY AND CLINICAL PRESENTATION | 286 | ||
| ALZHEIMER’S DISEASE: PATHOLOGY AND EPIDEMIOLOGY | 290 | ||
| REFERENCES | 294 | ||
| ADDITIONAL RESOURCES | 299 | ||
| CHAPTER 18. Drug Treatment for Depression and Anxiety | 300 | ||
| DEPRESSION | 300 | ||
| ANXIETY DISORDERS AND SEDATIVE AND ANXIOLYTIC DRUGS | 309 | ||
| REFERENCES | 313 | ||
| CHAPTER 19. Drug Treatment for Schizophrenia and Bipolar Illness | 317 | ||
| ANTIPSYCHOTIC DRUGS AND SCHIZOPHRENIA | 317 | ||
| BIPOLAR DISORDER | 327 | ||
| REFERENCES | 330 | ||
| ADDITIONAL RESOURCES | 332 | ||
| SECTION SIX Anti-Infective and Anti-Cancer Agents | 333 | ||
| CHAPTER 20. Antimicrobial Agents | 334 | ||
| CHARACTERISTICS AND CLASSIFICATION OF BACTERIA | 334 | ||
| PROPERTIES OF ANTIBIOTICS | 335 | ||
| DRUG-RESISTANT BACTERIA | 338 | ||
| FACTORS TO CONSIDER IN THE CHOICE OF AN ANTIMICROBIAL AGENT | 339 | ||
| SUPERINFECTION | 340 | ||
| MAJOR ANTIMICROBIAL AGENTS | 340 | ||
| SOME SPECIFIC BACTERIAL INFECTIONS AND THEIR TREATMENT | 346 | ||
| ANTIMICROBIAL PROPHYLAXIS IN SURGERY | 349 | ||
| PROPER USE OF ANTIBIOTICS | 349 | ||
| PREVENTING ANTIBIOTIC RESISTANCE AND SPREAD OF INFECTION | 349 | ||
| ADVERSE EFFECTS OF ANTIBIOTICS AND THERAPEUTIC CONCERNS | 350 | ||
| REFERENCES | 351 | ||
| CHAPTER 21. Antiviral Agents and Selected | 353 | ||
| TREATMENT OF VIRAL INFECTIONS | 353 | ||
| DRUGS AND FUNGAL INFECTIONS | 370 | ||
| REFERENCES | 373 | ||
| CHAPTER 22. Cytotoxic Agents and Immune | 376 | ||
| ETIOLOGY AND PATHOPHYSIOLOGY OF CANCER | 376 | ||
| CYTOTOXIC STRATEGY IN CANCER THERAPY | 377 | ||
| CANCER THERAPY TREATMENT GOALS AND EVALUATION OF RESPONSE | 378 | ||
| CONSEQUENCES OF CANCER THERAPY | 379 | ||
| RESISTANCE TO CANCER THERAPY | 379 | ||
| CHEMOTHERAPY (ANTINEOPLASTIC) DRUG CLASSES | 380 | ||
| TUMOR IMMUNOTHERAPY | 394 | ||
| CANCER THERAPY ADVERSE EFFECTS, RECOMMENDATIONS FOR TREATMENT, AND REHAB THERAPY IMPLICATIONS | 398 | ||
| IMMUNOSUPPRESSION | 407 | ||
| REFERENCES | 408 | ||
| SECTION SEVEN Special Topics in Pharmacology | 411 | ||
| CHAPTER 23. Drugs for Gastrointestinal Disorders | 412 | ||
| PHYSIOLOGIC CONTROL OF DIGESTION | 412 | ||
| ACID-RELATED DISEASE AND ITS TREATMENT | 414 | ||
| NAUSEA AND VOMITING | 418 | ||
| DIARRHEA | 420 | ||
| CONSTIPATION | 421 | ||
| IRRITABLE BOWEL SYNDROME | 422 | ||
| THERAPEUTIC CONCERNS ABOUT GASTROINTESTINAL AGENTS | 424 | ||
| REFERENCES | 425 | ||
| CHAPTER 24. Vitamins and Minerals | 427 | ||
| BIOCHEMICAL FUNCTIONS OF VITAMINS AND MINERALS | 427 | ||
| DEFINITION OF MULTIVITAMINS/MULTIMINERALS | 427 | ||
| USE OF MULTIVITAMINS/MULTIMINERALS | 428 | ||
| REFERENCE INTAKES OF VITAMINS AND MINERALS IN THE HEALTHY POPULATION | 428 | ||
| VITAMIN AND MINERAL BIOAVAILABILITY | 428 | ||
| RISKS OF INADEQUATE INTAKE OF VITAMINS AND MINERALS | 428 | ||
| MICRONUTRIENT STATUS CHANGES AS A RESULT OF DISEASE | 429 | ||
| CONSEQUENCES OF NUTRITIONAL DEFICIENCIES OF VITAMINS OR MINERALS | 429 | ||
| ROLE OF MVM SUPPLEMENTS ON NUTRIENT ADEQUACY | 430 | ||
| PREVALENCE OF INTAKES AT RISK OF BEING EXCESSIVE | 430 | ||
| FOOD/NUTRIENT–DRUG INTERACTIONS | 430 | ||
| REFERENCES | 435 | ||
| CHAPTER 25. Topical Drugs and Treatments | 437 | ||
| PHYSIOLOGY AND PATHOPHYSIOLOGY OF WOUNDS | 437 | ||
| CREATING THE IDEAL WOUND ENVIRONMENT FOR HEALING | 438 | ||
| SPECIFIC CONCERNS AND ADJUVANT INTERVENTIONS FOR CHRONIC WOUNDS | 440 | ||
| SPECIAL CONSIDERATIONS FOR THE REHABILITATION PROFESSIONAL | 443 | ||
| CONCLUSION | 445 | ||
| REFERENCES | 446 | ||
| CHAPTER 26. Complementary and Alternative Medicine in Pharmacology | 448 | ||
| INTRODUCTION | 448 | ||
| EVIDENCE-BASED REVIEW OF SELECTED SUPPLEMENTS | 450 | ||
| SUPPLEMENTS FOR CARDIOVASCULAR DISEASE | 456 | ||
| FINDING SUPPLEMENT INFORMATION AND ADVISING PATIENTS | 468 | ||
| REFERENCES | 468 | ||
| CHAPTER 27. Drugs of Abuse: Anabolic Steroids and Other Doping Agents | 478 | ||
| DEFINITIONS | 478 | ||
| ALCOHOL | 479 | ||
| TOBACCO | 479 | ||
| MARIJUANA | 480 | ||
| HEROIN | 481 | ||
| COCAINE | 481 | ||
| HALLUCINOGENIC SUBSTANCES | 481 | ||
| INHALANTS | 482 | ||
| ANABOLIC STEROIDS | 482 | ||
| “STREET DRUG” TOXICITY | 482 | ||
| IMPLICATIONS FOR REHABILITATIVE THERAPISTS | 483 | ||
| REFERENCES | 483 | ||
| CHAPTER 28. Exploring Drug–Exercise Interactions | 485 | ||
| INTERACTIONS BETWEEN SELECTIVE CARDIOPULMONARY AND DIABETIC MEDICATIONS AND EXERCISE | 485 | ||
| CARDIAC MEDICATIONS | 486 | ||
| PULMONARY MEDICATIONS | 489 | ||
| DIABETES MEDICATIONS | 492 | ||
| REFERENCES | 498 | ||
| INDEX | 503 |